Navigation Links
ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis
Date:4/10/2008

Follows Canadian regulatory approval of the ATS 3f Valve

MINNEAPOLIS, April 10 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the first North American commercial implant of the ATS 3f(R) Aortic Bioprosthesis. Canadian regulatory approval was received at the end of December, 2007. The first implant was performed by Benoit de Varennes, MD, MSc, FRSC, Chairman, Division of Cardiac Surgery at McGill University in Montreal, Canada. The patient was a 76-year-old man with aortic valve stenosis. The valve replacement was successful and the patient has been discharged from the hospital in good condition.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

The ATS 3f Aortic Bioprosthesis incorporates revolutionary design concepts intended to preserve native aortic root geometry and function. Through this unique approach, the prosthesis more closely mimics native valve function providing excellent hemodynamic performance that may contribute to improvements in key determinants of cardiovascular performance such as coronary blood flow and left ventricular mass regression. Data suggests that physiologic stresses, a detriment to bioprosthetic valve longevity, may be more efficiently distributed throughout the prosthetic's leaflets.

"The ATS 3F valve incorporates important characteristics of many other valves all in one product. The hemodynamic characteristics are very good and the valve offers the potential for longer durability. Previous stentless valve designs appeared to have good hemodynamic performance, but compl
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
2. MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
3. Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device
4. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
5. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
6. Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus
7. ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million
8. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
9. Tryton Medical, Inc. Closes $14 Million Financing
10. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
11. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... Schering-Plough Assumes Exclusive Worldwide Marketing Rights for ... N.J., May 19 Schering-Plough Corporation (NYSE: ... to its global collaboration with Novartis for ... therapies for the treatment of asthma and ...
... May 18 Solvay Pharmaceuticals announces it ... a company specialized in enabling and accelerating global ... China. Through this agreement, Solvay Pharmaceuticals will gain ... specifically on compounds in the cardiovascular area. ...
... Entire ALS Community to Join a Nationwide Network of ... ALS Therapy Development Institute (ALS TDI) announced its ... designed to increase the awareness and understanding of ALS ... To accomplish its goal, the campaign brings together three ...
Cached Biology Technology:Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 2Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 3Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 2Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 3
(Date:7/24/2014)... new study has identified two factors that characterize ... the production of highly qualified physics teachers. Specifically, ... champion physics teacher education in combination with institutional ... remain viable. Science, Technology, Engineering and Math (STEM) ... the study points the way for institutions seeking ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... are elementary building blocks of life. They often perform ... to fold into three-dimensional structures. Misfolding of proteins leads ... strategies did nature develop over the course of evolution ... chemist Dr. Frauke Grter (Heidelberg Institute for Theoretical Studies) ...
... January 31, 2013 -- Deborah E. Wiley, Chair of ... JWa & JWb), announced today that the twelfth annual ... Dr. Michael Young, Rockefeller University, Dr. Jeffrey Hall, Brandeis ... The Wiley Prize is being awarded to Dr. Young, ...
... N.C. In the last decade, a new strain of ... everyone at risk of contracting the dangerous bacterial infection. This ... a chunk of genes not shared by any other strains, ... the bacteria to survive and persist in the community. ...
Cached Biology News:Protein origami: Quick folders are the best 2Protein origami: Quick folders are the best 312th annual Wiley Prize in Biomedical Sciences awarded 212th annual Wiley Prize in Biomedical Sciences awarded 3UNC study may lead to treatments that are effective against all MRSA strains 2
... ShortCut RNase III, used with its manganese-containing ... a heterogeneous mix of short (1825 bp) ... in mammalian cells. 1.3 units (1 l) ... convert 1 g of dsRNA into siRNA ...
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
Biology Products: